Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Maria Sharapova Enrolls At Harvard Business School

  • The fallout from Maria Sharapova Meldonium episode is reaching a head
  • The 29-year-old star failed a drugs test during Australian Open 
  • Former world number one is expected to learn her fate this coming week 
  • Sharapova episode only compounded an already difficult year for tennis
  • Sharapova has enrolled for a two-week programme

Last March, Sharapova revealed that she tested positive for the banned substance meldonium during the Australian Open,The tennis star tested positive for Meldonium, a drug she had been taking for the past decade known for improving blood flow and she has subsequently be banned from the sport for two years by the ITF.

Sharapova has enrolled for a two-week programme to divert her attention from the ban.

The 29-year-old Russian tennis star posted a photo on Twitter on Saturday, next to the Harvard Business school’s sign, writing, “Not sure how this happened but Hey Harvard! Can’t wait to start the program!

Sharapova wrote on Facebook that she plans to appeal the ban and hopes to get back on the court in less than two years.

“While the tribunal concluded correctly that I did not intentionally violate the anti-doping rules, I cannot accept an unfairly harsh two-year suspension. The tribunal, whose members were selected by the ITF, agreed that I did not do anything intentionally wrong yet they seek to keep me from playing tennis for two years. I will immediately appeal the suspension portion of this ruling to CAS, the Court of Arbitration for Sport,” she wrote on June 8. “I have missed playing tennis and I have missed my amazing fans, who are the best and most loyal fans in the world.

This post first appeared on Social Discussion Platform| Forum | Troopel, please read the originial post: here

Share the post

Maria Sharapova Enrolls At Harvard Business School


Subscribe to Social Discussion Platform| Forum | Troopel

Get updates delivered right to your inbox!

Thank you for your subscription